Australian Broker Call *Extra* Edition – Aug 14, 2025

This story features ASTRAL RESOURCES NL, and other companies.
For more info SHARE ANALYSIS: AAR
The company is included in ALL-ORDS

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

AAR   ARX   CAR   CQE (2)   CVN   ERD   GLL   IRE   JBH   MM8   NUZ   PLT   PXA   RWC   TPW   WGX  

AAR    ASTRAL RESOURCES NL

Gold & Silver – Overnight Price: $0.17

Canaccord Genuity rates ((AAR)) as Buy (1) –

Canaccord Genuity notes Astral Resources’ latest assay results highlight more opportunity to increase resources at the three deposits at the Feysville project attached to the Mandilla gold project. 

In June, the company released the pre-feasibility study (PFS) for the Mandilla gold project which outlined annual production of 76koz/annum at cost of $2,085/oz over an initial 19-year operation.

The broker reckons the latest results will support the PFS.

Buy. Target price 64c (was 49c in April, before it was raised to 64c in early July).

This report was published on August 11, 2025.

Target price is $0.64 Current Price is $0.17 Difference: $0.47
If AAR meets the Canaccord Genuity target it will return approximately 276% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 17.00.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 17.00.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ARX    AROA BIOSURGERY LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.64

Wilsons rates ((ARX)) as Overweight (1) –

Wilsons maintained its Overweight rating on Aroa Biosurgery following positive June quarter updates from its peers and competitors.

The broker notes US commercial partner TELA Bio is showing strong momentum, especially with PRS product expansion planned over several years. 

The company itself is building a Myriad product family for high-value surgical indications where infection-resistant, implantable devices are most compelling to surgeons.

On the regulatory side, the broker believes the US Centers for Medicare & Medicaid Services’ proposed reforms to curb the skin substitutes market could level the playing field and open opportunities for Symphony.

Minor changes to forecasts. Target price 82c.

This report was published on August 12, 2025.

Target price is $0.82 Current Price is $0.64 Difference: $0.18
If ARX meets the Wilsons target it will return approximately 28% (excluding dividends, fees and charges).
The company’s fiscal year ends in March.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.18 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 349.73.

Forecast for FY27:

Wilsons forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.27 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 233.58.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CAR    CAR GROUP LIMITED

Automobiles & Components – Overnight Price: $40.04

Jarden rates ((CAR)) as Neutral (3) –

After detailed analysis of CAR Group’s FY25 result, Jarden notes operating momentum remains strong with FY26 net profit guidance of 9-13% growth comparing with consensus of 12% before the result.

For FY26, the broker is forecasting 13.2% revenue growth vs guidance of 12-14%, and group EBITDA of 12.5% vs 10-13% guidance. North American organic revenue growth was the focus, and the broker estimates 11.6% revenue and 12.3% EBITDA growth.

The broker also forecasts margin expansion in Australia and Latin America. Overall, FY26 EPS forecast trimmed by -1.9% and FY27 by -3.6%, mainly due to below-the-line items. 

Neutral. Target unchanged at $34.50.

This report was published on August 12, 2025.

Target price is $34.50 Current Price is $40.04 Difference: minus $5.54 (current price is over target).
If CAR meets the Jarden target it will return approximately minus 14% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $42.14, suggesting upside of 5.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 90.00 cents and EPS of 115.70 cents.
At the last closing share price the estimated dividend yield is 2.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 34.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 110.9, implying annual growth of 52.0%.
Current consensus DPS estimate is 88.8, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 36.1.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 99.00 cents and EPS of 123.40 cents.
At the last closing share price the estimated dividend yield is 2.47%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 32.45.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 126.6, implying annual growth of 14.2%.
Current consensus DPS estimate is 101.3, implying a prospective dividend yield of 2.5%.
Current consensus EPS estimate suggests the PER is 31.6.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CQE    CHARTER HALL SOCIAL INFRASTRUCTURE REIT

Childcare – Overnight Price: $3.24

Jarden rates ((CQE)) as Neutral (3) –

Charter Hall Social Infrastructure REIT’s FY25 result met expectations but FY26 DPU guidance beat forecasts by 4.6%.

Jarden notes the REIT is well placed to capture net operating income growth, with 28% of its income due for market rent reviews over the next three years.

The broker’s conservative forecast for weighted average rent review is 3.7% for FY26, with upside risk, vs 4.2% in FY25, but higher than 3.4% in FY24.

Overall, the broker sees upside risk to its forecast for 6% FFO compounded annual rate for FY25-28.

Neutral. Target lifted to $3.35 from $3.25 on model roll-forward and increase in FFO forecasts for FY26-28.

This report was published on August 11, 2025.

Target price is $3.35 Current Price is $3.24 Difference: $0.11
If CQE meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 16.80 cents and EPS of 16.90 cents.
At the last closing share price the estimated dividend yield is 5.19%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.17.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 17.20 cents and EPS of 17.30 cents.
At the last closing share price the estimated dividend yield is 5.31%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.73.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

---

Moelis rates ((CQE)) as Downgrade to Hold from Buy (3) –

Charter Hall Social Infrastructure REIT’s FY25 results were in line with guidance, but FY26 distribution guidance was 5% higher than Moelis’ forecast.

The broker notes like-for-like rents rose 4.3% in FY25 vs 3.4% in FY24, and while most of FY26-27 rent reviews are capped, net operating income is still estimated to be above 3% long-term.

Upgrades to forecasts are largely driven by asset remixing and lower interest rate outlook.

Target price $3.39. Rating downgraded to Hold from Buy.

This report was published on August 12, 2025.

Target price is $3.39 Current Price is $3.24 Difference: $0.15
If CQE meets the Moelis target it will return approximately 5% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Moelis forecasts a full year FY26 dividend of 16.80 cents and EPS of 16.90 cents.
At the last closing share price the estimated dividend yield is 5.19%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.17.

Forecast for FY27:

Moelis forecasts a full year FY27 dividend of 17.30 cents and EPS of 17.50 cents.
At the last closing share price the estimated dividend yield is 5.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.51.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CVN    CARNARVON ENERGY LIMITED

Crude Oil – Overnight Price: $0.11

Canaccord Genuity rates ((CVN)) as Downgrade to Hold from Speculative Buy (3) –

Canaccord Genuity notes key milestones for Carnarvon Energy during the June quarter included up to 19.99% strategic investment in Strike Energy ((STX)) for up to -$89m.

The broker doesn’t see prospect for material synergies, should there be a merger in future, and believes the company didn’t properly articulate the rationale behind the current investment.

The company is investigating alternative options to accelerate the Dorado development and is working with the JV partners. The quarter ended with $97m in cash post the Strike investment, and no debt.

Rating downgraded to Hold from Speculative Buy. Target cut to 14c from 26c.

This report was published on August 11, 2025.

Target price is $0.14 Current Price is $0.11 Difference: $0.03
If CVN meets the Canaccord Genuity target it will return approximately 27% (excluding dividends, fees and charges).

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ERD    EROAD LIMITED

Transportation & Logistics – Overnight Price: $2.00

Canaccord Genuity rates ((ERD)) as Buy (1) –

New Zealand plans to legislate in 2026 a transition of all 3.5m light passenger vehicles to electronic road user charging (eRUC) by 2027. Canaccord Genuity believes the legislation has bi-partisan support, making implementation risk low.

Eroad has a 92% market share of eRUC in NZ, and the broker reckons it will be a big beneficiary due to first mover advantage, incumbency and integration with government and private stakeholders.

The broker lifted FY28 EBIT by 14% with upside risk as the opportunity is de-risked.

Buy. Target rises to NZ$3 from NZ$2.

This report was published on August 8, 2025.

Current Price is $2.00. Target price not assessed.
The company’s fiscal year ends in March.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.38 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 45.62.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 7.95 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.17.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

GLL    GALILEE ENERGY LIMITED

NatGas – Overnight Price: $0.01

Canaccord Genuity rates ((GLL)) as Hold (3) –

Canaccord Genuity notes Galilee Energy made slow progress with the Glenasas pilot and has now acknowledged it cannot continue funding the project on a 100% basis.

The company is now open for investment interest in the project.

Hold. Target unchanged at 3c.

This report was published on August 11, 2025.

Target price is $0.03 Current Price is $0.01 Difference: $0.02
If GLL meets the Canaccord Genuity target it will return approximately 200% (excluding dividends, fees and charges).

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

IRE    IRESS LIMITED

Wealth Management & Investments – Overnight Price: $8.80

Wilsons rates ((IRE)) as Overweight (1) –

Wilsons observes there were too many details in Iress’ 1H25 result, arguing key messages unfortunately got lost within, but the main positive was accelerating revenue growth, belying market scepticism.

FY25 adjusted EBITDA guidance was reiterated, with implication it will be 2H-weighted to achieve the top end of the $127-135m range. If this is achieved, the broker will be more comfortable with its $140m adjusted EBITDA estimate for FY26.

Still, there was a downgrades to FY25-26 forecasts due to removal of loss-making Quanthouse and higher effective tax rates.

Target price unchanged at $10 due to private equity interest in the company. Overweight retained.

This report was published on August 12, 2025.

Target price is $10.00 Current Price is $8.80 Difference: $1.2
If IRE meets the Wilsons target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $9.73, suggesting upside of 10.6%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 35.00 cents and EPS of 35.20 cents.
At the last closing share price the estimated dividend yield is 3.98%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 35.5, implying annual growth of -26.0%.
Current consensus DPS estimate is 21.1, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 24.8.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 41.00 cents and EPS of 40.20 cents.
At the last closing share price the estimated dividend yield is 4.66%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.89.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 39.2, implying annual growth of 10.4%.
Current consensus DPS estimate is 23.8, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 22.4.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

JBH    JB HI-FI LIMITED

Consumer Electronics – Overnight Price: $113.96

Jarden rates ((JBH)) as Neutral (3) –

After beating expectations with FY25 result, Jarden notes JB Hi-Fi’s outlook is brightened by three key tailwinds: replacement demand, interest rate cuts and rising activity in housing.

Other positives includes new game releases, strong forward orders and AI revolution. The broker lifted FY26-28 EPS forecasts by 0.5% following strong FY25 result and sees FY26 risks to the upside.

Neutral. Target rises to $95.70 from $95.50.

This report was published on August 11, 2025.

Target price is $95.70 Current Price is $113.96 Difference: minus $18.26 (current price is over target).
If JBH meets the Jarden target it will return approximately minus 16% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $104.94, suggesting downside of -7.9%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 357.00 cents and EPS of 467.40 cents.
At the last closing share price the estimated dividend yield is 3.13%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 463.5, implying annual growth of 9.6%.
Current consensus DPS estimate is 357.8, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 24.6.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 382.00 cents and EPS of 499.10 cents.
At the last closing share price the estimated dividend yield is 3.35%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.83.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 488.6, implying annual growth of 5.4%.
Current consensus DPS estimate is 389.3, implying a prospective dividend yield of 3.4%.
Current consensus EPS estimate suggests the PER is 23.3.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

MM8    MEDALLION METAL LIMITED

Gold & Silver – Overnight Price: $0.30

Canaccord Genuity rates ((MM8)) as Speculative Buy (1) –

Medallion Metals’ Forrestania transaction with IGO Ltd ((IGO)) is now binding. 

The company will acquire full legal and beneficial ownership of the Forrestania tenements, plant and infrastructure with no upfront or deferred cash, aside from a 1.5% royalty on future gold production.

IGO reserves the right to explore for, develop and mine nickel and lithium over Forrestania. The deal will be completed by the end of the year.

Canaccord Genuity notes the company has $29m in cash after completing $27.5m share placement at 21c.

Speculative Buy. Target rises to 80c from 65c, after the broker removed its previous forecast for $52.5m equity raise.

This report was published on August 8, 2025.

Target price is $0.80 Current Price is $0.30 Difference: $0.5
If MM8 meets the Canaccord Genuity target it will return approximately 167% (excluding dividends, fees and charges).

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

NUZ    NEURIZON THERAPEUTICS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.17

Petra Capital rates ((NUZ)) as Buy (1) –

Petra Capital observes Neurizon Therapeutics is moving on manufacturing preparation for NUZ-001, well ahead of when most small biotechs typically would.

The company is preparing three registration batches at 1:10 scale to satifsy regulatory requirements, but is following commercial manufacturing processes. The purpose is to prove consistency between batches.

The broker notes the Elanco deal essentially removes major supply and scale-up risks while saving cost, and being commercial-ready will be especially relevant if accelerated approval is an option.

Buy. Target price 50c.

This report was published on August 12, 2025.

Target price is $0.50 Current Price is $0.17 Difference: $0.33
If NUZ meets the Petra Capital target it will return approximately 194% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 3.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.67.

Forecast for FY26:

Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 3.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.31.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PLT    PLENTI GROUP LIMITED

Business & Consumer Credit – Overnight Price: $1.12

Moelis rates ((PLT)) as Re-initiation of coverage with Buy (1) –

Moelis has re-initiated coverage of Plenti Group with a Buy rating and target price of $1.53.

The broker notes the lender’s loan book has grown strongly to over $2.5bn in FY25 from $614m in FY21. It is on track to grow further to $3bn by FY26 and to $5bn by 2Q29.

Commentary suggests the company has already shown cost discipline and net interest revenue is estimated to grow at 14.8% annual rate over FY26-28 and net profit at 30.9% compounded annual growth rate.

The broker notes the lender is partnered with National Australia Bank ((NAB)) to grow auto loans, seen as a material opportunity.

This report was published on August 12, 2025.

Target price is $1.53 Current Price is $1.12 Difference: $0.41
If PLT meets the Moelis target it will return approximately 37% (excluding dividends, fees and charges).
The company’s fiscal year ends in March.

Forecast for FY26:

Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 10.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.47.

Forecast for FY27:

Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.57.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PXA    PEXA GROUP LIMITED

Real Estate – Overnight Price: $15.67

Jarden rates ((PXA)) as Overweight (2) –

Jarden reiterates NatWest’s onboarding is a critical milestone for Pexa Group, but there’s now further upside potential from the strategic review of the Digital Solutions business under new CEO.

The broker also believes there’s slight upside risk to FY25 EBITDA margins if costs are controlled, as higher settlement volumes makes it likely revenue will meet its forecast.

Near term D&A forecasts increase due to increase in guidance to -$103-105m from -$98-102m.

Overweight. Target unchanged at $17.75.

This report was published on August 11, 2025.

Target price is $17.75 Current Price is $15.67 Difference: $2.08
If PXA meets the Jarden target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $15.74, suggesting upside of 0.5%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 19.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 82.47.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 5.5, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 284.9.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 15.20 cents and EPS of 39.30 cents.
At the last closing share price the estimated dividend yield is 0.97%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 39.87.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 39.2, implying annual growth of 612.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 40.0.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RWC    RELIANCE WORLDWIDE CORP. LIMITED

Building Products & Services – Overnight Price: $4.46

Jarden rates ((RWC)) as Overweight (2) –

Jarden had a re-look at its forecast for US tariff impact on Reliance Worldwide, lowering it to unmitigated FY26 cost impact of -US$60m from -US$135m previously estimated.

The broker reckons cost mitigation will come from diverting supply chain from China, cost-cuts and single-digit price hikes.

FY25-28 EPS forecasts trimmed by -5.6% on lower FY26 revenue growth and tariff cost impacts in FY26-27.

Overweight. Target price $4.80.

This report was published on August 11, 2025.

Target price is $4.80 Current Price is $4.46 Difference: $0.34
If RWC meets the Jarden target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $5.06, suggesting upside of 13.4%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 6.96 cents and EPS of 27.53 cents.
At the last closing share price the estimated dividend yield is 1.56%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.20.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 28.6, implying annual growth of N/A.
Current consensus DPS estimate is 7.3, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 15.6.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 6.65 cents and EPS of 22.89 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.48.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 28.4, implying annual growth of -0.7%.
Current consensus DPS estimate is 7.3, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 15.7.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TPW    TEMPLE & WEBSTER GROUP LIMITED

Furniture & Renovation – Overnight Price: $26.07

Canaccord Genuity rates ((TPW)) as No Rating (-1) –

Ahead of Temple & Webster’s FY25 result, Canaccord Genuity has placed the rating and target under preview.

The broker believes the sales growth rate going into FY26 will be the main focus at the result, with its forecast at 23% y/y. In the first four months of 2H25, the growth rate was 18%, below consensus of 23%, largely affected by US tariff announcements.

The broker is forecasting FY25 revenue of $607m and expects the company to be on the path to meet its medium-term revenue growth target of $1bn over the next 3-5 years.

This report was published on August 12, 2025.

Current Price is $26.07. Target price not assessed.
Current consensus price target is $20.70, suggesting downside of -20.6%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 3.00 cents and EPS of 14.00 cents.
At the last closing share price the estimated dividend yield is 0.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 186.21.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 9.8, implying annual growth of 553.3%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 266.0.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 3.00 cents and EPS of 22.00 cents.
At the last closing share price the estimated dividend yield is 0.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 118.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 17.7, implying annual growth of 80.6%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 147.3.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

WGX    WESTGOLD RESOURCES LIMITED

Gold & Silver – Overnight Price: $2.97

Canaccord Genuity rates ((WGX)) as Buy (1) –

Westgold Resources’ FY26 production guidance of 345-385koz compared with Canaccord Genuity’s forecast of 369koz, prompting the broker to lower it by -1%.

Cost guidance of $2,600-2,900/oz compared with the broker’s $2,731/oz, resulting in a 2% increase to $2,779/oz. Capex forecast was a big miss, and the broker lifted it by 35% to align with the -$270m guidance.

The company will release feasibility study on the Higginsville mill expansion and make a final investment decision in late FY26. In September, it plans to provide a three-year outlook.

Buy. Target cut to $5.25 from $5.35 (was $4.40 in early May).

This report was published on August 11, 2025.

Target price is $5.25 Current Price is $2.97 Difference: $2.28
If WGX meets the Canaccord Genuity target it will return approximately 77% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 2.00 cents and EPS of 12.00 cents.
At the last closing share price the estimated dividend yield is 0.67%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.75.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 3.00 cents and EPS of 58.00 cents.
At the last closing share price the estimated dividend yield is 1.01%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.12.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Click to view our Glossary of Financial Terms